Q-omics provides the consensus-scored P2RY11 profile across patient tissues and cancer cell-line models. P2RY11 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, P2RY11 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, P2RY11 RNA expression shows 16,672 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where P2RY11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RY11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RY11 survival associations across molecular data types. P2RY11 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RY11 RNA expression–survival associations across cancer types. High P2RY11 expression shows unfavorable associations in KIRC, ACC, UCS and LGG, but favorable associations in BLCA and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for P2RY11 RNA expression.
This table summarizes P2RY11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for P2RY11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RY11 shows higher tumor expression in KIRC, STAD, COAD, LIHC, KIRP and BRCA. The KIRC box plot shows higher P2RY11 RNA expression in tumor versus normal tissue (log2 FC = +0.629, t-test p < 0.001).
This table shows molecular features associated with P2RY11 in patient tissues and cancer cell lines. In patient samples, P2RY11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, P2RY11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
